nutrients-logo

Journal Browser

Journal Browser

Osteoporosis and Elderly Metabolism and Nutrition

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: closed (20 August 2021) | Viewed by 6247

Special Issue Editor


E-Mail Website
Guest Editor
Bone-metabolic Research Unit, Department of Endocrinology, Rigshospitalet and Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark
Interests: osteporosis; ageing; bone metabolism; calcium homeostasis; nutrition; metabolism; breast cancer; aromatase inhibitors; glucocorticoids

Special Issue Information

Dear Colleagues,

Economic growth around the world is improving health in general, healthcare, education, and nutrition. People around the world are getting older; therefore, healthcare for the elderly should be improved. Better treatment options are extending the life of patients suffering from chronic diseases such as cancer, heart failure, and other major diseases. Osteoporosis is one of the chronic diseases that will increasingly affect the ageing population as a primary disease, as well as patients suffering from other chronic conditions, as a secondary disease. This Special Issue will focus on osteoporosis in the elderly and on how a more extensive knowledge of metabolism and nutrition might improve the prophylaxis and treatment of bone loss and prevent fractures due to primary or secondary osteoporosis.

Prof. Dr. Peter Schwarz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteoporosis
  • nutrition
  • metabolism
  • supplementation
  • chronic disease
  • elderly
  • old
  • diabetes
  • chronic obstructive lung disease
  • cancer

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 495 KiB  
Article
Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy—Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort
by Kristian Buch-Larsen, Trine Lund-Jacobsen, Michael Andersson and Peter Schwarz
Nutrients 2021, 13(8), 2902; https://doi.org/10.3390/nu13082902 - 23 Aug 2021
Cited by 6 | Viewed by 2773
Abstract
Women with breast cancer are a growing population due to improved screening and treatment. It has been described that chemotherapy can negatively affect patients’ metabolism. The aim of this study is to assess weight gain during chemotherapy treatment in an interim analysis on [...] Read more.
Women with breast cancer are a growing population due to improved screening and treatment. It has been described that chemotherapy can negatively affect patients’ metabolism. The aim of this study is to assess weight gain during chemotherapy treatment in an interim analysis on an ongoing prospective cohort of women with early breast cancer. To help untangle the many possible reasons for weight change, we examine blood tests, Patient-Reported Outcomes (PROs), and bone mineral density (BMD). We find that the 38 women that have measurements taken after chemotherapy have an average weight gain of 1.2 kg although not significant. Together with this, there is a significant drop in HDL cholesterol, an increase in triglycerides, and a non-significant tendency towards decreased insulin sensitivity. PROs show that although the women experience more pain and fatigue, they have higher activity levels. BMD is at an expected level according to age. All in all, we see an increased focus on physical activity and nutrition, leading to less severe metabolic changes as previously reported. However, even though more measures are taken, we still see an overall negative metabolic impact with unknown long-term implications. Full article
(This article belongs to the Special Issue Osteoporosis and Elderly Metabolism and Nutrition)
Show Figures

Figure 1

9 pages, 1393 KiB  
Article
Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
by Antonino Catalano, Federica Bellone, Domenico Santoro, Peter Schwarz, Agostino Gaudio, Giorgio Basile, Maria Carmela Sottile, Sabrina Atena Stoian, Francesco Corica and Nunziata Morabito
Nutrients 2021, 13(6), 1878; https://doi.org/10.3390/nu13061878 - 31 May 2021
Cited by 8 | Viewed by 2898
Abstract
Vitamin D modulates bisphosphonate (BP) efficacy, but its contribution to bone mineral density (BMD) after BP discontinuation is not known. To address this topic, we performed a retrospective analysis of postmenopausal women exposed to alendronate (ALN) to treat osteoporosis who regularly continued the [...] Read more.
Vitamin D modulates bisphosphonate (BP) efficacy, but its contribution to bone mineral density (BMD) after BP discontinuation is not known. To address this topic, we performed a retrospective analysis of postmenopausal women exposed to alendronate (ALN) to treat osteoporosis who regularly continued the supplementation of cholecalciferol or calcifediol at recommended doses. In the ninety-six recruited women (age 61.1 ± 6.9 years), ALN was administered for 31.2 ± 20.6 months and then discontinued for 33.3 ± 18.9 months. The modification of 25(OH)D serum levels over time was associated with a change of alkaline phosphatase (r = −0.22, p = 0.018) and C-terminal collagen type 1 telopeptide (r = −0.3, p = 0.06). Women in the tertile of the highest increase in 25(OH)D level showed a 5.7% BMD gain at lumbar spine, that was twice as great in comparison with participants with a lower 25(OH)D variation. At a multiple regression analysis, BMD change was associated with time since menopause (ß = 2.28, SE 0.44, p < 0.0001), FRAX score for major fracture (ß = −0.65, SE 0.29, p = 0.03), drug holiday duration (ß = −2.17, SE 0.27, p < 0.0001) and change of 25(OH)D levels (ß = 0.15, SE 0.03, p = 0.0007). After ALN discontinuation, improving the vitamin D status boosts the ALN tail effect on BMD. Full article
(This article belongs to the Special Issue Osteoporosis and Elderly Metabolism and Nutrition)
Show Figures

Figure 1

Back to TopTop